go short Response in as early as 1 month*
DURABLE, COMPLETE RESPONSES
beyond 10 years 1
Important Safety Information
Therapy with Proleukin (aldesleukin) should be
restricted to patients with normal cardiac and
testing and formal pulmonary function testing.
Extreme caution should be used in patients with a
normal thallium stress test and a normal pulmonary
function test who have a history of cardiac or
pulmonary disease.
Proleukin should be administered in a hospital
experienced in the use of anticancer agents.
An intensive care facility and specialists skilled in
cardiopulmonary or intensive care medicine must
be available.
Proleukin administration has been associated with
capillary leak syndrome (CLS) which is characterized
by a loss of vascular tone and extravasation of plasma
results in hypotension and reduced organ perfusion
which may be severe and can result in death. CLS may
be associated with cardiac arrhythmias (supraventricular
†
References: 1. 2. Lindsey KR, Rosenberg SA, Sherry RM. Impact of the number
of treatment courses on the clinical response of patients who receive high-dose bolus interleukin-2. J Clin Oncol.